Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum
Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15 years, led by AbbVie’s blockbuster anti-TNF inhibitor treatment Humira (adalimumab).
Therapy Watch launches a new wave of EU tracking in Psoriasis (PsO)
A panel of 40 dermatologists in each of the major EU markets reports on patients on advanced therapies including biologics and small molecule therapies every quarter.
In addition from Q1 2019 Therapy Watch will now be tracking prescription topical treatments in both a secondary care and primary care setting providing broad visibility of the psoriasis market landscape.
Infographic: Psoriasis (PsO)
An overview of the PsO advanced therapy and systemic patient
Our PsO market snapshot offers an introduction to the real world patient data collected by our Therapy Watch PsO study. The snapshot features profile data for patients treated with advanced therapy agents and systemic agents.
Infographic: Rheumatoid arthritis (RA)
An overview of the RA biologic patient
Our RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at twelve of the key indices captured in Therapy Watch data.
Are dual ARVs the new frontier in a maturing HIV market?
Tackling and managing HIV has been one of the pharmaceutical industry’s more distinguished achievements, despite the turbulence and antagonism that marked the early days of AIDS-related R&D and the industry’s relationships with governments, patients and activists.
Therapy Watch Associate Director Raquel Nuñez, discusses continuing improvements in HIV therapies and the evolution of single-tablet regimens (STRs) over time.